Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Late annual account NBB
Fiscal year 2024 was filed 425 days after the legal deadline.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2024.
Financials
Financial year 2024
CONMED Europe from Drogenbos, company number BE0463420369, closed financial year 2024 with a result of € 4.7 million after tax. For that financial year CONMED Europe recorded revenue of € 39.7 million and equity of € 129.2 million. Compared with financial year 2023, the result moved from € 2.9 million to € 4.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.
€ 129.2 million
▲ 4% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 4.7 million
▲ 60% vs 2023
Profit after tax over the fiscal year.
€ 1.3 million
▲ 63% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € -40.1 million.
People and assets in 2024
48.7
▲ 1 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 5.3 million
▲ 1% vs 2023
€ 108,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 358,333
▼ 10% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 1.4 million
▼ 10% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 16 days on average.
€ 1.5 million
▼ 3% vs 2023
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 21,482,527 | € 25,558,194 | € 36,914,723 | € 39,740,601 | ▲ 8% |
| Profit after taxes | € 509,666 | € -15,150,149 | € 2,943,343 | € 4,714,501 | ▲ 60% |
| Equity | € 136,687,529 | € 121,537,381 | € 124,480,724 | € 129,195,225 | ▲ 4% |
| Total debts | € 7,601,532 | € 6,537,453 | € 7,847,760 | € 2,994,945 | ▼ 62% |
| Cash | € 498,674 | € 649,518 | € 804,767 | € 1,314,179 | ▲ 63% |
| Retained profit | € -32,657,165 | € -47,807,314 | € -44,863,971 | € -40,149,469 | ▲ € 4.7 million |
| Bank debt | € 0 | € 0 | € 3,800,000 | € 0 | ▼ 100% |
| Balance sheet total | € 144,300,733 | € 128,083,570 | € 132,339,385 | € 132,207,101 | |
| Employees (FTE) | 53.8 | 54 | 47.7 | 48.7 | ▲ 1 |
Key figures of CONMED Europe, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to CONMED Europe?
What happened at CONMED Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 4.7 million (▲ 60% vs 2023). filed late Source: NBB ↗
- Johonna Pelletier stepped down as director. NBB
- Andrew David Kearns became a director. NBB
- Stephane Epinette stepped down as director. NBB
- Sven Van Kets became a director. NBB
- Patrick J. Beyer stepped down as director. NBB
- Stephane Epinette became a director. NBB
- Heather L. Cohen stepped down as director. NBB
In short
From € 509,666 profit in 2021 to € 4.7 million profit in 2024.
Paid € 474,566 in corporate taxes since 2021.
Best year ever: 2024, with € 4.7 million profit.
Pays suppliers within 16 days on average.
Management
Behind CONMED Europe are Andrew David Kearns and Sven Van Kets. The shares are held by Linvactec Belgium (100%). It owns 100% of LINVATEC AUSTRIA GMBH, 100% of CONMED DEUTSCHLAND GMBH, 100% of Linvatec Conmed Sweden AB, 100% of LINVATEC POLSKA SP. ZOO, 100% of CONMED Switzerland GmbH and 100% of LINVATEC DENMARK APS itself.
Directors
According to the 2024 annual accounts
since 2025
since 2025
since 2018 · until 2026
Patrick J. Beyer
Director
since 2015 · until 2025
since 2025 · until 2025
since 2023 · until 2024
Shareholders
100%
Participations
LINVATEC AUSTRIA GMBH
100%
CONMED DEUTSCHLAND GMBH
100%
Linvatec Conmed Sweden AB
100%
LINVATEC POLSKA SP. ZOO
100%
CONMED Switzerland GmbH
100%
LINVATEC DENMARK APS
100%
CONMED FRANCE SAS
100%
CONMED UK LTD
100%
CONMED LINVATEC AUSTRALIA PTY LTD
100%
Establishments
Establishment units
Physical locations of this company
W.A. Mozartlaan 3
1620 Drogenbos
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
MICROSOFT-CORP-MSN-AS-BLOCK - Microsoft Corporation, US
Domain
Domain
conmed.com
Registered
1995-10-12
Registrar
Network Solutions, LLC
Expires
2030-10-11
Website info
Features
Security
Details
- Company number
- 0463.420.369
- VAT number
- BE 0463.420.369
- Registered office
- W.A. Mozartlaan 3, 1620 Drogenbos
- Names & denominations
- CONMED Europe
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 20 May 1998
- Peppol
- Active · Active since 3 Dec 2025
- Contact
- conmed.com
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Coördinatiecentra
Activiteiten van hoofdkantoren